MustGrow Biologics sees strong potato yield gains – ICYMI

MustGrow Biologics (TSX-V:MGRO, OTCQB:MGROF) reported that large-scale field trials of its TerraSante biofertility product in Washington and Idaho potatoes yielded roughly a two‑ton per acre increase, a higher proportion of marketable A/B-sized tubers and fewer culls. At an estimated $180/acre treatment cost the trials corresponded to more than $5,000/acre in yield value—exceeding a typical 4:1 ROI—supporting the company’s claim of soil‑microbiome benefits and driving farmer word‑of‑mouth adoption as MustGrow plans to scale trials and commercial rollouts into California and other U.S. regions in 2026–27.

Analysis

MustGrow Biologics reported large-scale field-trial results for its TerraSante biofertility product in Washington and Idaho potatoes, citing roughly a two-ton per acre yield uplift, higher proportions of marketable A/B tuber sizes and fewer culls. The company and growers estimate treatment economics at about $180 per acre versus an implied yield value of over $5,000 per acre, producing an ROI materially above the 4:1 agronomy benchmark the COO referenced.

Management attributes the results to positive effects on soil health and the microbiome and says farmer word-of-mouth is driving localized adoption; MustGrow expects a commercial ramp in 2026–27 including California and additional U.S. regions. These operational comments support a pathway from trials to scaled acreage, but conversion depends on agronomist/retailer engagement and growers increasing treated acres after initial small trials.

Sentiment around the release is moderately positive (per-signal MGROF 0.5; market-impact score 0.28), indicating constructive reaction but limited immediate market disruption. Key near-term risks are replication of results across geographies and crops, the timeline to monetize acreage at scale, and execution of distribution and supply to meet anticipated 2026–27 ramp; investors should monitor follow-up trial data, acreage under commercial contract, and any third-party validations.

Key Decisions for Investors

• Consider a measured, size-limited long exposure to MGROF to capture upside from the reported economics, but limit position until the company converts trials into demonstrable paid acreage growth
• Monitor near-term commercialization signals—follow-up trial results in California and other regions, acreage under contract, retailer/agronomist endorsements and any third-party validations that confirm the ~2-ton/acre gains and >$5,000/acre value
• Apply risk controls such as position limits or hedges given modest market-impact and execution risk, and be prepared to reduce exposure if subsequent trials fail to replicate results or if realized per-acre economics diverge from the reported figures